Project Grant R21CA293623
- This federal Project Grant award of $192,564 from the National Cancer Institute (NCI), under the Cancer Research Manpower (CFDA 93.398) program, supports research at Yale University to develop an innovative dual-target PROTAC-based protein degrader targeting lineage plasticity drivers in metastatic castration-resistant prostate cancer (mCRPC). The research aims to simultaneously inhibit multiple oncogenic drivers responsible for therapy resistance driven by lineage plasticity, a key mechanism...
- This federal Project Grant award of $387,500.00 from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) supports research to determine the molecular mechanisms that regulate the activity of protein kinases. The research will use the Hippo pathway, which controls decisions of cell fate and number, as a model system to investigate different mechanisms that modulate the activity of protein kinases. The goal is to accelerate the...
- This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) supports research to define key components of the PRMT5 axis that impair cell viability upon PRMT5 inhibition and identify pathways that can restore viability in MTAP-deleted cancer cells. The $442,089 award to Yale University will leverage a genome-scale CRISPR activation platform to identify genes that modulate sensitivity to PRMT5 pathway inhibition. The research aims to...
- The federal Project Grant award of $396,854 from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) aims to develop innovative nanopore tweezer tools for analyzing the structural dynamics of disease-associated kinases and screening allosteric inhibitors. The University of Massachusetts, the primary awardee, will leverage its expertise in protein analysis and structural biology to create novel nanopore-based sensors capable...
- This federal Project Grant award, funded by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research), supports research at the Sloan-Kettering Institute for Cancer Research to investigate the oncogenic role of the TYK2 fusion protein in lymphoma development. The $3,111,184 award, spanning from September 2025 to August 2029, aims to advance the understanding of how the NPM1::TYK2 fusion drives the pathogenesis of mature T-cell lymphomas, specifically anaplastic large cell lymphoma....
- This Project Grant award of $656,304 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to the Weill Medical College of Cornell University supports comprehensive research aimed at understanding the fundamental biological mechanisms underlying cancer development, progression, and potential interventions. The research project, titled "Signal Transduction to p70 S6 Kinase 1", will explore the role of the mTOR complex 1 (mTORC1) protein kinase complex in...
- This $449,726 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports the development of innovative tools to enable the rapid, high-sensitivity mapping of changes in protein interactions within living cells. The University of Illinois is the primary awardee and will leverage advanced biotinylation techniques, including light-regulated and engineered biotin ligases, to facilitate the real-time analysis of dynamic changes in protein...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $1,625,853 to New York University (NYU) to conduct research aimed at understanding the fundamental biological mechanisms underlying cancer development, progression, and potential interventions. The project will leverage advanced 3D chromatin analysis techniques to map and characterize "3D regulatory hubs" - DNA elements that interact with multiple loci and coordinate...
- The University of Pittsburgh received a $151,920 Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Biology Research program (CFDA 93.396), to conduct research on characterizing the conformational changes induced by inhibitor binding on the Src-family kinases associated with acute myeloid leukemia (AML). The research aims to investigate strategies utilizing nuclear magnetic resonance (NMR) spectroscopy to probe the allosteric effects of inhibitor binding on...
- This federal Project Grant award for $478,532.00, awarded by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research), supports research by Yale University to investigate the biological and clinical significance of spatial immune heterogeneity in non-small cell lung cancer. The project aims to elucidate how the spatial positioning and distribution of tumor-infiltrating lymphocytes and B-cells within the tumor microenvironment impact disease progression and response to...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $391,531 to Yale University to develop technology for directing phosphorylation of specific protein kinase substrates. The goal is to engineer a kinase mutant that can selectively phosphorylate a designer allele of one of its substrates, using knowledge of kinase phosphorylation site specificity. The researchers will establish the feasibility of this approach using the tumor suppressor kinase LKB1 and its substrate AMPK as a model system. The project aims to create a system where a single kinase substrate is phosphorylated with the same dynamics as the native substrate, enabling studies of how the kinase functions in cancer. This innovative technology will ultimately be applied to other protein kinases implicated in cancer. The award period runs from August 6, 2024 to July 31, 2026.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $391.5k | 8/6/24 |